LONDON, October 10, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
The U.S. equity market closed on a mixed note on Wednesday, October 9, 2013; with the S&P 500 and the Dow Jones Industrial Average posting marginal gains, while the NASDAQ Composite ended lower. Shares in the biotechnology industry ended mostly lower, even as the broader market finished on a mixed note. MannKind Corporation (NASDAQ: MNKD), Galena Biopharma Inc. (NASDAQ: GALE), Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), and Novavax Inc. (NASDAQ: NVAX), were amongst the major movers in the industry. AAAResearchReports.com initiated preliminary technical research on MNKD, GALE, ARIA, and NVAX. These free reports are accessible by signing today at:
MannKind Corp.'s stock posted gains on Wednesday, reversing some of the losses from the previous trading session. The company's shares vacillated between $4.37 and $4.78 before ending the day 1.28% higher at $4.74. A total of 8.47 million shares were traded, which is above the daily average volume of 7.24 million. The company's shares have lost 11.90% in the previous three trading sessions, underperforming the S&P 500 which has lost 2.02% during the same period. Moreover, MannKind Corp.'s stock is trading below its 50-day and 200-day moving averages of $6.27 and $4.89, respectively. The free technical analysis on MNKD is available by signing up at:
Shares in Galena Biopharma Inc. fell by 2.82% on Wednesday, even as the U.S. equity market finished on a mixed note. The company's shares closed the day at $2.07, after oscillating between $2.01 and $2.17. A total of 3.40 million shares were traded, which is above the daily average volume of 2.61 million. The company's shares have declined 1.43% in the previous three months, underperforming the S&P 500 which has advanced 0.25% during the same period. Additionally, Galena Biopharma Inc.'s stock is trading below its 50-day and 200-day moving averages of $2.12 and $2.08, respectively. Register now to download free research on GALE at:
Ariad Pharmaceuticals Inc.'s stock heavily plummeted on Wednesday, extending its losses from the previous trading session. The company's shares closed the day at $5.83, down 65.99%, after oscillating between $4.00 and $6.10. A total of 114.86 million shares were traded, which is significantly above the daily average volume of 2.82 million. The company's shares have lost 68.99% in the previous three trading sessions, compared to a loss of 2.02% in the S&P 500 during the same period. Furthermore, Ariad Pharmaceuticals Inc.'s stock is trading significantly below its 50-day and 200-day moving averages of $19.25 and $19.12, respectively. A free report on ARIA can be accessed by registering at:
Shares in Novavax Inc. also plummeted on Wednesday, ending the session 7.52% lower than the previous day's price of $3.06. The company's shares oscillated between $2.80 and $3.07 before closing the day at $2.83. A total of 5.07 million shares were traded, which is significantly above the daily average volume of 2.89 million. Despite Wednesday's losses, the company's shares have gained 10.98% in the previous three months, outperforming the S&P 500 which has gained 0.25% during the same period. Additionally, Novavax Inc.'s stock is trading above its 200-day moving average of $2.33. Register with AAA Research Reports and download research on NVAX for free at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to making mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE AAA Research Reports